Guhan Pharmaceutical Group (000590) Stock Overview
Manufactures and sells traditional Chinese medicines, chemical drugs, and health food in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
000590 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Guhan Pharmaceutical Group Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥12.28 |
| 52 Week High | CN¥15.25 |
| 52 Week Low | CN¥7.09 |
| Beta | 0.30 |
| 1 Month Change | 6.14% |
| 3 Month Change | 3.89% |
| 1 Year Change | 65.50% |
| 3 Year Change | 32.19% |
| 5 Year Change | 70.79% |
| Change since IPO | 207.62% |
Recent News & Updates
Recent updates
Optimistic Investors Push Tus-Pharmaceutical Group Co., Ltd. (SZSE:000590) Shares Up 32% But Growth Is Lacking
Mar 03
More Unpleasant Surprises Could Be In Store For Tus-Pharmaceutical Group Co., Ltd.'s (SZSE:000590) Shares After Tumbling 25%
Dec 25Tus-Pharmaceutical Group Co., Ltd.'s (SZSE:000590) 37% Price Boost Is Out Of Tune With Revenues
Nov 08Tus-Pharmaceutical Group's (SZSE:000590) Solid Profits Have Weak Fundamentals
Apr 03Revenues Not Telling The Story For Tus-Pharmaceutical Group Co., Ltd. (SZSE:000590) After Shares Rise 27%
Mar 08Shareholder Returns
| 000590 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 11.1% | 0.2% | -1.4% |
| 1Y | 65.5% | 18.0% | 28.9% |
Return vs Industry: 000590 exceeded the CN Pharmaceuticals industry which returned 18% over the past year.
Return vs Market: 000590 exceeded the CN Market which returned 28.9% over the past year.
Price Volatility
| 000590 volatility | |
|---|---|
| 000590 Average Weekly Movement | 3.5% |
| Pharmaceuticals Industry Average Movement | 4.2% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in CN Market | 9.7% |
| 10% least volatile stocks in CN Market | 3.1% |
Stable Share Price: 000590 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 000590's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1956 | 1,159 | Xue Feng | guhan.com |
Guhan Pharmaceutical Group Co., Ltd., together with its subsidiaries, manufactures and sells traditional Chinese medicines, chemical drugs, and health food in China. It operates through the Production and Sales of Traditional Chinese Medicine; Production and Sales of Western Medicine; and Other Operations segments. The company offers prescription and over-the-counter drugs, such as tonic and health-preserving drugs, cardiovascular and cerebrovascular drugs, children's nutrition drugs, cold drugs, and heat-clearing and detoxifying drugs.
Guhan Pharmaceutical Group Co., Ltd. Fundamentals Summary
| 000590 fundamental statistics | |
|---|---|
| Market cap | CN¥2.82b |
| Earnings (TTM) | -CN¥111.84m |
| Revenue (TTM) | CN¥351.79m |
Is 000590 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 000590 income statement (TTM) | |
|---|---|
| Revenue | CN¥351.79m |
| Cost of Revenue | CN¥186.92m |
| Gross Profit | CN¥164.87m |
| Other Expenses | CN¥276.71m |
| Earnings | -CN¥111.84m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Mar 31, 2026
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 46.87% |
| Net Profit Margin | -31.79% |
| Debt/Equity Ratio | 18.2% |
How did 000590 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/09 11:41 |
| End of Day Share Price | 2026/02/09 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Guhan Pharmaceutical Group Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chase Ding | HSBC |
| Hai Zhu Peng | Huatai Research |